Suxamethonium dosage in electroconvulsive therapy

Area of Science:

• Anesthesiology
• Neurology
• Pharmacology

Background:

• Electroconvulsive therapy (ECT) is a medical treatment for severe mental health conditions.
• Neuromuscular blocking agents are used during ECT to prevent injury.
• Suxamethonium is a common neuromuscular blocking agent, but optimal dosing for ECT requires investigation.

Purpose of the Study:

• To compare the effects of different suxamethonium doses (15 mg, 25 mg, 50 mg) during electroconvulsive therapy (ECT).
• To evaluate the impact of suxamethonium dosage on respiratory recovery and seizure modification.
• To determine the optimal suxamethonium dose for ECT procedures.

Main Methods:

• A double-blind, randomized study involving 52 patients undergoing 180 ECT treatments.
• Patients received suxamethonium at doses of 15 mg, 25 mg, or 50 mg.
• Outcomes measured included time to spontaneous respiration and quality of seizure modification.

Main Results:

• The 50 mg suxamethonium group had significantly longer recovery times compared to lower doses.
• Higher suxamethonium doses (50 mg) were associated with better seizure modification than the 15 mg dose.
• No significant differences in post-treatment muscle pain were observed across dose groups.

Conclusions:

• All tested suxamethonium doses (15 mg, 25 mg, 50 mg) were deemed acceptable for ECT.
• A 25 mg dose of suxamethonium presents practical advantages over 50 mg and theoretical benefits over 15 mg.
• The 25 mg dose offers a favorable balance between respiratory recovery and seizure modification in ECT.